Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Initial triple oral therapy versus dual oral therapy in newly diagnosed pulmonary arterial hypertension
NL-OMON45816Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of macitentan, tadalafil and selexipag in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Ratio of Week 26 to baseline pulmonary vascular resistance. Started Nov 2017; status: completed.
02
Drugs
macitentantadalafilselexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON45816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45816.